Response in breast vs axilla after neoadjuvant treatment and implications for nonoperative management of invasive breast cancer.

Improved imaging and neoadjuvant chemotherapy (NAT) have led to higher pathologic complete response rates (pCR) in patients with invasive breast cancer. This has questioned the necessity of surgery and axillary lymph node (ALN) dissection in these patients. Prospective clinical trials are implementi...

Descripción completa

Detalles Bibliográficos
Publicado en:Breast Journal Vol. 27; no. 2; pp. 120 - 126
Autores principales: Schmidt, Hank, Zhaveri, Shruti, Valente, Christopher, Pisapati, Kereeti, Pickholz, Eliana, Weltz, Sarah, Nayak, Anupma, Oza, Twisha, Corben, Adriana, Weltz, Christina, Port, Elisa, Jaffer, Shabnam
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Feb2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148724199&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 148724199
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1075122X
        ET6
      jtl: Breast Journal
      issn: 1075122X
      maglogo: Y
    pubinfo:
      dt: Feb2021
      vid: 27
      iid: 2
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        148724199
        148587281
        148724199
        148724199
        10.1111/tbj.14125
        148724199
      ppf: 120
      ppct: 6
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Response in breast vs axilla after neoadjuvant treatment and implications for nonoperative management of invasive breast cancer.
      aug:
        au:
          Schmidt, Hank
          Zhaveri, Shruti
          Valente, Christopher
          Pisapati, Kereeti
          Pickholz, Eliana
          Weltz, Sarah
          Nayak, Anupma
          Oza, Twisha
          Corben, Adriana
          Weltz, Christina
          Port, Elisa
          Jaffer, Shabnam
        affil: Breast Surgical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York NY,, USA
      sug:
        subj:
          Breast Neoplasms Drug Therapy
          Neoplasm Invasiveness Drug Therapy
          Chemotherapy, Adjuvant
          Breast Neoplasms Pathology
          Treatment Outcomes
          Human
          Descriptive Statistics
          Carcinoma
          Axillary Lymph Node Dissection
          Biological Markers
          Axilla Pathology
          Neoplasm Metastasis
          Tumor Burden
          HER-2-neu Oncogene
          Phenotype
          Record Review
      ab: Improved imaging and neoadjuvant chemotherapy (NAT) have led to higher pathologic complete response rates (pCR) in patients with invasive breast cancer. This has questioned the necessity of surgery and axillary lymph node (ALN) dissection in these patients. Prospective clinical trials are implementing extensive core biopsies of the tumor bed of patients with clinical complete response as a means to identify and spare them breast surgery. In addition, it is anticipated that patients with pCR are most likely going to have no or minimal disease in ALN as well. To verify the feasibility of these trials, we performed a pathologic analysis of all our patients who have undergone NAT from 2009 to present. Using pathology data base, we identified 362 patients treated with neoadjuvant chemotherapy followed by surgery. Clinical and pathologic information including gross and microscopic descriptions as well as biomarker status was collected. pCR was 50% for patients with negative ALN pretreatment but only 28% for patients with positive ALN at diagnosis. Despite achieving pCR in the breast, up to 10% of patients with positive ALN and 1% with negative ALN had persistent disease. Eight percent of patients that were presumed to have no ALN disease either clinically and or by imaging were found to have metastatic carcinoma in ALN. The metastases were predominantly (80%) <5 mm, and not palpable on physical examination and or due to biopsy sampling error. pCR in breast and ALN directly correlated with tumor size, ALN disease, and Her2 positive and triple negative receptor phenotype. In breast cancer patients who are node positive at time of diagnosis with pCR in the breast after neoadjuvant chemotherapy, residual lymph node disease was very uncommon. Further study is warranted to select patients who may avoid breast and axillary surgery post neoadjuvant chemotherapy.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N